Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension
Changpeng Zhu(Shanghai Changzheng Hospital), Wei‐Fen Xie(Second Military Medical University), Jordi Gracia‐Sancho(University Hospital of Bern), Zoe Boyer‐Díaz, Peio Aristu-Zabalza(Departament de Salut), Xin Zhang(Shanghai Changzheng Hospital), Shaohua Song(Shanghai Jiao Tong University), Hai-Lin Xiong(Shanghai Changzheng Hospital), Keqi Wang(Shanghai Changzheng Hospital), Cheng Luo(Chinese Academy of Sciences), Ji-Feng Feng(Shanghai Changzheng Hospital), Weihua Dong(Shanghai Changzheng Hospital), Shuqing Liu(Chengdu University of Traditional Chinese Medicine), Wansheng Chen(Second Military Medical University)
Cited by 12
Related Papers
Chinese Consensus Report on Family-Based<i>Helicobacter pylori</i>Infection Control and Management (2021 Edition)
|Gut|2021|183
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
An HNF1α-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells
|Cell Research|2015|82
The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1
|Molecular Cancer|2018|69
Tanreqing Inhibits LPS-Induced Acute Lung Injury In Vivo and In Vitro Through Downregulating STING Signaling Pathway
|Frontiers in Pharmacology|2021|45